Protein production teams, get ready to move faster and more efficiently to deliver high-quality recombinant proteins! We’re excited to bring you Andromeda X, now with Spectral Shift technology, to help you optimize protein expression for all of your drug discovery workflows. Learn more: https://bit.ly/3whayEf
NanoTemper Technologies
Biotechnologieforschung
Tools made for drug discovery. Built for momentum.
Info
At NanoTemper, our vision is to help create a world where every disease is treatable. For us, that starts by equipping scientists with reliable tools that bring them the clarity, confidence, and momentum they need to discover future therapies, even difficult ones. That’s why we build our tools with high-quality materials that give scientists the clearest results. We make our tools easy-to-learn. And, we support customers with strong scientific know-how throughout their journey. Since 2008, research teams at top biotech and pharmaceutical companies, as well as leading research institutions around the world, have used NanoTemper tools to get ahead in their research. Because the path to a disease-free world requires courage, big thinking, and collaboration, our values guide our work, our culture, and our commitment to help customers solve their biggest challenges. Every team member at NanoTemper, in every department, contributes to giving our customers momentum to discover therapies. That means everyone has an opportunity to make a big impact in their role, in their career, and for the world. But it’s not always easy — and it can only be done if we work together. That’s why finding a company full of people that not only work hard but enjoy spending time with each other is so important. At NanoTemper, our culture is very collaborative and one where we respect each other’s work. Ensuring that everyone has the support to do their job well is always top of mind. We’re headquartered in Munich, Germany with representation in countries around the world including the United Kingdom, Poland, France, United States, Japan, China, and India. If you’re looking to make a big impact in a collaborative setting, NanoTemper is the place for you! Imprint: https://nanotempertech.com/imprint/
- Website
-
https://nanotempertech.com/
Externer Link zu NanoTemper Technologies
- Branche
- Biotechnologieforschung
- Größe
- 201–500 Beschäftigte
- Hauptsitz
- Munich
- Art
- Privatunternehmen
Orte
-
Primär
Toelzer Str. 1
Munich, 81379, DE
-
400 Oyster Point Blvd.
Suite 336
South San Francisco, CA 94080, US
-
9 Galen St
Suite 317A
Watertown, Massachusetts 02472, US
Beschäftigte von NanoTemper Technologies
Updates
-
NanoTemper Technologies hat dies direkt geteilt
From 7 weeks to 48 hours: our journey to lightning-fast delivery When you order something, you want to have it. And you want to have it soon. The last years, it took us 7 weeks on average to ship our devices to EU and US customers. This was slow. This was not as fast, as our customer wanted and needed it. This was bad. Today, we've cut that down to just 48 hours: 48 hours from receiving an order to shipping the instrument. How did we do it in just six months? 1. Streamlined Operations: Enabled better demand planning and streamlined our production. 2. Enhanced Efficiency: Optimized our process flows and automated key steps. 3. Teamwork Makes the Dream Work: None of this would be possible without our incredible team and their seamless collaboration. This isn't just a win for us. It is a huge leap forward for our customers. We ensure that you get what you need faster than ever. Proud of our team and what we've achieved together! #biotechnology #entrepreneurship #startup ————————— I am Philipp - founder, CEO & business angel. My bootstrapped company NanoTemper is a global leader for biophysical tools for biotech. Like my content? Click my name + follow + 🔔
-
-
Could targeted protein degradation (TPD) be the key to treating neurodegenerative diseases (NDs) like Alzheimer’s and Parkinson’s? Most TPD research has focused on combatting cancer, but proof-of-concept studies have already shown that degraders are a viable modality to treat NDs. However, some challenges need to be addressed before degraders targeting NDs can reach the clinic. Things like the blood-brain barrier and lack of central nervous system specific E3 ligases make degrader development for NDs tricky. This mini-review published in Frontiers in Molecular Neurosciences explores the therapeutic potential of PROTACs and molecular glues for NDs, highlighting their advantages over traditional small molecule inhibitors and the challenges ahead. Read the full publication here: https://lnkd.in/gJTEZTw7
-
When screening fragments, it's critical to distinguish true hits from artifacts so you maximize the chances of creating a successful therapeutic. So, what should you consider when choosing hit cut-offs during single-dose screens? R&D scientist Nathan Adams from NanoTemper shares his insights on identifying true hits with Spectral Shift technology.
-
G Protein-Coupled Receptors (GPCRs) are well-established as effective drug targets, but their inherent complexity poses significant challenges for binding measurements. Here are four reasons why conventional methods often fall short and why alternative approaches are essential: 1️⃣ GPCRs are membrane proteins: GPCRs are membrane-bound, making them amphipathic and challenging to solubilize. Traditional techniques often fail to maintain their solubility, leading to unreliable results. Advanced methods are required to handle these solubility challenges effectively. 2️⃣ GPCRs have a complex structure: The structural intricacies of GPCRs are difficult to study in isolation. Their dynamic nature means that traditional static analysis techniques can't capture the full picture. Innovative technologies that allow for real-time, structural analysis are needed to better understand these receptors. 3️⃣ GPCRs display intricate modes of action: GPCRs engage in complex signaling pathways, including dimerization, transduction, and three-way interactions. Traditional binding studies can overlook these multifaceted interactions. Comprehensive approaches that account for these complexities are essential for accurate drug targeting. 4️⃣ GPCRs need alternative expression strategies The difficulty in producing GPCRs in high yields leads to reliance on alternative expression systems, often resulting in lower yields and the need for detergent-heavy buffers. This makes it crucial to use methods that maximize receptor production while preserving function. If you're working with GPCRs, how do you currently address the challenges above?
-
Working on developing your next bispecific antibody? In a recent publication scientists from DTU - Technical University of Denmark describe a comprehensive set of complementary methods to study Bispecific mAbs critical quality attributes (CQAs) including thermal stability and aggregation propensity. Among other tools, their study highlight the value of Prometheus Panta for simultaneous thermal and colloidal stability measurements with high-throughput and very low material consumption, crucial in the developability assessment of bispecifics. The authors state "Importantly, the simultaneous monitoring of aggregation during unfolding, as illustrated in Figure 2, favors in-depth understanding of the antibody behavior and developability profile." Read the publication here: https://lnkd.in/eybphcZY
Generation of robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds: a comprehensive comparison of formats
tandfonline.com
-
NanoTemper Technologies hat dies direkt geteilt
Hot off the press excitement for #structuralbiology combining NanoTemper Technologies label-free thermal unfolding #nanoDSF with #CryoEM! 🎆 A global team of researchers from Stockholm University, Harvard University, Boston Children's Hospital and Ipsen Bioinnovation just published this exciting work in Nature Portfolio's Communication Chemistry investigating a new botulinum neurotoxin serotype, BoNT/X, with promising therapeutic properties, and how the presence or absence of it's protective partner protein (NTNH) that stabilized the BoNT/X affects potency. Read more about this exciting #research here: https://lnkd.in/g9rfPNv8 #biophysics #protein #toxin #therapeutic #teamwork
-
-
NanoTemper Technologies hat dies direkt geteilt
I've asked: "Biotech 2020 - 2024: from heaven to hell?" - Now, let's extend our view to 2019 - SURPRISE: it does NOT look like hell. I've used ChatGPT to analyze the quarterly numbers from the companies Waters Corporation, Bio-Techne, Sartorius, Danaher, Agilent, and Thermo Fisher from 2019 to now. These companies provide tools for pharma and biotech - like our company NanoTemper Technologies does. We see 3 phases: 2019 and before: The Pre-Pandemic "normal". I've normalized everything to the 1st quarter in 2019. 2020-2022: The Highs The biotech industry soared during the pandemic. Money flowed like never before. We were in a golden age—innovation, expansion, optimism. It felt like nothing could go wrong. We were all riding high. 2023-2024: The Transition The tide turns. Layoffs in pharma. Biotech is running out of funding. Everyone has to fight hard for every dollar. Some companies are doing well - like Bio-Techne. Some companies suffer, like Agilent. It is a mixed and complex pattern. When I've wrote "we are in a crisis" 2 months ago: Did I miss the big picture? Have I been blinded by the years of hype? Compared to 2019 we are at a high level. Maybe not heaven anymore. But still paradise? How do you interprete the data? #biotechnology #entrepreneurship #startup ————————— I am Philipp - founder, CEO & business angel. My bootstrapped company NanoTemper is a global leader for biophysical tools for biotech. Like my content? Click my name + follow + 🔔
-
-
NanoTemper Technologies hat dies direkt geteilt
1st summer in our new Headquarters +30°C hot Munich summer. 7 weeks of Bavarian vacations. 4 month in our new HQ. Just delivered fastest drug screening instrument of the world. That means: perfect time to relax and to enjoy some Espresso and ice cream. In this hidden object fun picture you can find: 1x the strongest coffee machine of the world. 2x Philipp’s with long hair. 4x different nations. 42x ice creams. Our NanoTemper Technologies team have had demanding months. Everyone did an awesome job - often until it hurt. We’ve - again - achieved what has been considered as impossible. A huge THANK YOU! We are proud of you! Now is the time to relax and to have fun. As Anjuli says: “Work hard - party harder!” #biotechnology #entrepreneurship #startup ————————— I am Philipp - founder, CEO & business angel. My bootstrapped company NanoTemper is a global leader for biophysical tools for biotech. Like my content? Click my name + follow + 🔔
-
-
NanoTemper Technologies hat dies direkt geteilt
Olympic record for drug discovery: A 1536 plate measured in 10 minutes. Highest speed of all biophysical instruments. 2 weeks of Olympics in Paris. 2 weeks of exceptional performances & records. The show must go on: We've just delivered our 1st ultra high throughput instrument. It measures a 1536 well plate in record time: 10 minutes including the plate handling steps. It is for drug screening and hit confirmation. It uses our Spectral Shift Technology. It is an optical method. It is in free solution. You want to know more? Please comment with "Dianthus uHTS" #biotechnology #entrepreneurship #startup ————————— I am Philipp - founder, CEO & business angel. My bootstrapped company NanoTemper is a global leader for biophysical tools for biotech. Like my content? Click my name + follow + 🔔
-